-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, Johnson & Johnson's Janssen company (Janssen) announced its IL-12/IL-23 inhibitor Stelara (ustekinumab) for the treatment of moderate to severe active ulcerative colitis (UC) patients with long-term extended research data
.
The data showed that more than half (55.
Ustekinumab developed by Janssen is a humanized IL-12 and IL-23 antibody
.
IL-12 and IL-23 are important cytokines that regulate the immune system and immune-mediated inflammatory diseases in the human body
"Despite substantial progress in recent years, many UC patients are still struggling to seek sustained relief of symptoms, especially treatments that do not require steroids
.
" said Dr.
Bruce E.
Reference materials:
Reference materials:[1] STELARA® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial.